Live Quote · NASDAQALLOHealthcare · Biotechnology

Allogene Therapeutics, Inc.

$2.08▼ 1.42%($-0.03)

TickerSpark Score

56/100

▌ Mixed

60

Valuation

20

Profitability

55

Growth

84

Health

60

Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALLO research report →

52-Week Range32% of range

Low

$0.98

Current

$2.08

High

$4.46

Company Overviewwww.allogene.com

About the company

Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy.

CEO: David D. Chang
IPO: 2018
Employees: 226
HQ: South San Francisco, CA, US

Price Chart

+73.33% · this period

Valuation

Market Cap: $507.25M
P/E: -2.70
P/S: 0.00
P/B: 1.79
EV/EBITDA: -3.48
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -56.45%
ROIC: -50.58%

Growth & Income

Revenue: $0 · -100.00%
Net Income: $-190,886,000 · 25.90%
EPS: $-0.87 · 34.09%
Op Income: $-206,933,000
FCF YoY: 25.55%

Performance & Tape

52W High: $4.46
52W Low: $0.98
50D MA: $2.10
200D MA: $1.80
Beta: 0.46
Avg Volume: 11.33M

Get TickerSpark's AI analysis on ALLO

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

Date	Insider	Role	Type	Shares	Value
Jun 18, 26	Kazam Joshua A	director	other	47,700	$0
Jun 18, 26	Kazam Joshua A	director	other	95,400	$0
Jun 18, 26	Kazam Joshua A	director	other	47,700	$0
Jun 18, 26	MESSEMER DEBORAH M.	director	other	95,400	$0
Jun 18, 26	Mayo Stephen	director	other	144,400	$288.80K
Jun 18, 26	SATO VICKI L	director	other	95,400	$0
Jun 18, 26	WITTE OWEN N.	director	other	95,400	$0
Jun 18, 26	Humer Franz B	director	other	95,400	$0
Jun 18, 26	Barrett Elizabeth A.	director	other	95,400	$0
Apr 21, 26	Yoshiyama Annie	officer: SVP, Finance	sell	9,586	$22.14K

Coverage · ALLO

Our ALLO coverage

Recent articles, reports, and earnings notes.

View all →

IPO

What to Watch as SL Science Holding Limited Prices on Nasdaq

SL Science Holding Limited Ordinary Shares (SLBT) is expected to list on Nasdaq on 2026-06-15, but the price range has not been disclosed. This is a de-SPAC listing rather than a traditional IPO, so the key question is whether the market gives credit to a small-revenue biotech platform with a very large headline valuation.